Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Supawat Thongthip maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $26 to $27.
Truist Securities analyst Supawat Thongthip maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $26 to $27.